- Report
- June 2026
- 383 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 288 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 287 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 575 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 390 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 419 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 395 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 395 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 483 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 380 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 211 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 275 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 246 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 190 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 126 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 291 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 193 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- August 2025
Global
From €4499EUR$4,950USD£3,880GBP
- Report
- May 2026
- 185 Pages
Global
From €4090EUR$4,500USD£3,527GBP
- Report
- January 2026
- 185 Pages
Global
From €4090EUR$4,500USD£3,527GBP

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body.
PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more